MovDisordV3, PascalFrancis, Curation, bibRecord, 000386

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

Identifieur interne : 000386 ( PascalFrancis/Curation ); précédent : 000385; suivant : 000387

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

Auteurs : William Koller [États-Unis] ; Andrew Lees [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie]

Source :

Movement disorders [ 0885-3185 ] ; 2001.

RBID : Pascal:02-0049768

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lévodopa, Chimiothérapie, Antiparkinsonien, Tolcapone, Inhibiteur enzyme, Catechol O-methyltransferase, Pergolide, Agoniste, Récepteur dopaminergique, Stimulant dopaminergique, Randomisation, Etude comparative, Traitement, Association médicamenteuse, Adulte, Toxicité, Ergot dérivé, Fluctuation motrice.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Agonist, Antiparkinson agent, Catechol O-methyltransferase, Chemotherapy, Comparative study, Dopamine agonist, Dopamine receptor, Drug combination, Enzyme inhibitor, Ergot derivatives, Levodopa, Parkinson disease, Pergolide, Randomization, Tolcapone, Toxicity, Treatment.

Abstract

In this 12-week, randomized, open-label, blinded-rater, parallel-group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.), with a possible increase to 200 mg t.i.d., or pergolide titrated to a maximum dose of 5 mg/day by week 9 (mean final dose 2.2 mg/day). The trial involved 203 patients. Efficacy variables that decreased from baseline to week 12 with tolcapone and pergolide included "off" time (reduced by 2-3 hours/day), daily levodopa intake, sickness impact profile scores, Parkinson's disease questionnaire (PDQ)-39 scores, and Unified Parkinson's Disease Rating Scale (UPDRS) scores. Improvements in efficacy variables were similar with tolcapone and pergolide, with the exception of improvements in quality of life, which were significantly greater with tolcapone; the relative changes in PDQ-39 score at week 12 were -8.7 and -14.2 (P < 0.05) with pergolide and tolcapone, respectively. Improvements in the investigator's global assessment (IGA) of overall efficacy were recorded in 86% of tolcapone-treated patients and in 78% of pergolide-treated patients. The proportion of patients who withdrew because of adverse events was higher in the pergolide group (15%) than in the tolcapone group (5%). Confusion, hypotension, nausea, constipation, abdominal pain, and dyspepsia occurred more frequently with pergolide, whereas diarrhea and urine discoloration occurred more frequently with tolcapone. Tolcapone was better tolerated than pergolide (P < 0.01) according to the IGA of overall tolerability. We conclude that, in this 3-month study, both tolcapone and pergolide provided improvements in motor fluctuations and allowed reductions in levodopa intake when added to levodopa therapy; intent to treat analysis and a less than maximal dose of pergolide may have biased the results in favor of tolcapone. Tolcapone provided greater improvements in quality of life, was better tolerated, and had a more favorable adverse-event profile than pergolide.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 16`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations`
A11	`01`	`1`		`@1 KOLLER (William)`
A11	`02`	`1`		`@1 LEES (Andrew)`
A11	`03`	`1`		`@1 DODER (Miroslava)`
A11	`04`	`1`		`@1 HELY (Mariese)`
A14	`01`			`@1 University of Miami @2 Miami, Florida @3 USA @Z 1 aut.`
A14	`02`			`@1 National Hospital for Neurology and Neurosurgery @2 London @3 GBR @Z 2 aut. @Z 3 aut.`
A14	`03`			`@1 Westmead Hospital @2 Sydney @3 AUS @Z 4 aut.`
A17	`01`	`1`		`@1 Tolcapone/Pergolide Study Group @3 INC`
A20				`@1 858-866`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000099256460080`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 27 ref.`
A47	`01`	`1`		`@0 02-0049768`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 In this 12-week, randomized, open-label, blinded-rater, parallel-group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.), with a possible increase to 200 mg t.i.d., or pergolide titrated to a maximum dose of 5 mg/day by week 9 (mean final dose 2.2 mg/day). The trial involved 203 patients. Efficacy variables that decreased from baseline to week 12 with tolcapone and pergolide included "off" time (reduced by 2-3 hours/day), daily levodopa intake, sickness impact profile scores, Parkinson's disease questionnaire (PDQ)-39 scores, and Unified Parkinson's Disease Rating Scale (UPDRS) scores. Improvements in efficacy variables were similar with tolcapone and pergolide, with the exception of improvements in quality of life, which were significantly greater with tolcapone; the relative changes in PDQ-39 score at week 12 were -8.7 and -14.2 (P < 0.05) with pergolide and tolcapone, respectively. Improvements in the investigator's global assessment (IGA) of overall efficacy were recorded in 86% of tolcapone-treated patients and in 78% of pergolide-treated patients. The proportion of patients who withdrew because of adverse events was higher in the pergolide group (15%) than in the tolcapone group (5%). Confusion, hypotension, nausea, constipation, abdominal pain, and dyspepsia occurred more frequently with pergolide, whereas diarrhea and urine discoloration occurred more frequently with tolcapone. Tolcapone was better tolerated than pergolide (P < 0.01) according to the IGA of overall tolerability. We conclude that, in this 3-month study, both tolcapone and pergolide provided improvements in motor fluctuations and allowed reductions in levodopa intake when added to levodopa therapy; intent to treat analysis and a less than maximal dose of pergolide may have biased the results in favor of tolcapone. Tolcapone provided greater improvements in quality of life, was better tolerated, and had a more favorable adverse-event profile than pergolide.
C02	`01`	`X`		`@0 002B02B05`
C02	`02`	`X`		`@0 235`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`04`	`X`	`FRE`	`@0 Antiparkinsonien @5 06`
C03	`04`	`X`	`ENG`	`@0 Antiparkinson agent @5 06`
C03	`04`	`X`	`SPA`	`@0 Antiparkinsoniano @5 06`
C03	`05`	`X`	`FRE`	`@0 Tolcapone @2 NK @2 FR @5 07`
C03	`05`	`X`	`ENG`	`@0 Tolcapone @2 NK @2 FR @5 07`
C03	`05`	`X`	`SPA`	`@0 Tolcapona @2 NK @2 FR @5 07`
C03	`06`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 08`
C03	`06`	`X`	`ENG`	`@0 Enzyme inhibitor @5 08`
C03	`06`	`X`	`SPA`	`@0 Inhibidor enzima @5 08`
C03	`07`	`X`	`FRE`	`@0 Catechol O-methyltransferase @2 FE @5 09 @6 Catechol «O»-methyltransferase`
C03	`07`	`X`	`ENG`	`@0 Catechol O-methyltransferase @2 FE @5 09 @6 Catechol «O»-methyltransferase`
C03	`07`	`X`	`SPA`	`@0 Catechol O-methyltransferase @2 FE @5 09 @6 Catechol «O»-methyltransferase`
C03	`08`	`X`	`FRE`	`@0 Pergolide @2 NK @2 FR @5 10`
C03	`08`	`X`	`ENG`	`@0 Pergolide @2 NK @2 FR @5 10`
C03	`08`	`X`	`SPA`	`@0 Pergolida @2 NK @2 FR @5 10`
C03	`09`	`X`	`FRE`	`@0 Agoniste @5 11`
C03	`09`	`X`	`ENG`	`@0 Agonist @5 11`
C03	`09`	`X`	`SPA`	`@0 Agonista @5 11`
C03	`10`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 12`
C03	`10`	`X`	`ENG`	`@0 Dopamine receptor @5 12`
C03	`10`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 12`
C03	`11`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 13`
C03	`11`	`X`	`ENG`	`@0 Dopamine agonist @5 13`
C03	`11`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 13`
C03	`12`	`X`	`FRE`	`@0 Randomisation @5 16`
C03	`12`	`X`	`ENG`	`@0 Randomization @5 16`
C03	`12`	`X`	`SPA`	`@0 Aleatorización @5 16`
C03	`13`	`X`	`FRE`	`@0 Etude comparative @5 17`
C03	`13`	`X`	`ENG`	`@0 Comparative study @5 17`
C03	`13`	`X`	`SPA`	`@0 Estudio comparativo @5 17`
C03	`14`	`X`	`FRE`	`@0 Traitement @5 18`
C03	`14`	`X`	`ENG`	`@0 Treatment @5 18`
C03	`14`	`X`	`SPA`	`@0 Tratamiento @5 18`
C03	`15`	`X`	`FRE`	`@0 Association médicamenteuse @5 19`
C03	`15`	`X`	`ENG`	`@0 Drug combination @5 19`
C03	`15`	`X`	`SPA`	`@0 Asociación medicamentosa @5 19`
C03	`16`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`16`	`X`	`ENG`	`@0 Adult @5 20`
C03	`16`	`X`	`SPA`	`@0 Adulto @5 20`
C03	`17`	`X`	`FRE`	`@0 Toxicité @5 23`
C03	`17`	`X`	`ENG`	`@0 Toxicity @5 23`
C03	`17`	`X`	`SPA`	`@0 Toxicidad @5 23`
C03	`18`	`X`	`FRE`	`@0 Ergot dérivé @5 31`
C03	`18`	`X`	`ENG`	`@0 Ergot derivatives @5 31`
C03	`18`	`X`	`SPA`	`@0 Ergot derivado @5 31`
C03	`19`	`X`	`FRE`	`@0 Fluctuation motrice @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Methyltransferases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Methyltransferases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Methyltransferases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Transferases @2 FE`
C07	`02`	`X`	`ENG`	`@0 Transferases @2 FE`
C07	`02`	`X`	`SPA`	`@0 Transferases @2 FE`
C07	`03`	`X`	`FRE`	`@0 Enzyme`
C07	`03`	`X`	`ENG`	`@0 Enzyme`
C07	`03`	`X`	`SPA`	`@0 Enzima`
C07	`04`	`X`	`FRE`	`@0 Homme`
C07	`04`	`X`	`ENG`	`@0 Human`
C07	`04`	`X`	`SPA`	`@0 Hombre`
C07	`05`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`07`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`07`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`07`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`08`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`08`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`08`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`09`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`09`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`09`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 021`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002935

Links to Exploration step

Pascal:02-0049768

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations</title>
<author><name sortKey="Koller, William" sort="Koller, William" uniqKey="Koller W" first="William" last="Koller">William Koller</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Miami</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Doder, Miroslava" sort="Doder, Miroslava" uniqKey="Doder M" first="Miroslava" last="Doder">Miroslava Doder</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Hely, Mariese" sort="Hely, Mariese" uniqKey="Hely M" first="Mariese" last="Hely">Mariese Hely</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Westmead Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0049768</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 02-0049768 INIST</idno>
<idno type="RBID">Pascal:02-0049768</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002935</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000386</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations</title>
<author><name sortKey="Koller, William" sort="Koller, William" uniqKey="Koller W" first="William" last="Koller">William Koller</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Miami</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Doder, Miroslava" sort="Doder, Miroslava" uniqKey="Doder M" first="Miroslava" last="Doder">Miroslava Doder</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Hely, Mariese" sort="Hely, Mariese" uniqKey="Hely M" first="Mariese" last="Hely">Mariese Hely</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Westmead Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Catechol O-methyltransferase</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Drug combination</term>
<term>Enzyme inhibitor</term>
<term>Ergot derivatives</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Pergolide</term>
<term>Randomization</term>
<term>Tolcapone</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Tolcapone</term>
<term>Inhibiteur enzyme</term>
<term>Catechol O-methyltransferase</term>
<term>Pergolide</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Stimulant dopaminergique</term>
<term>Randomisation</term>
<term>Etude comparative</term>
<term>Traitement</term>
<term>Association médicamenteuse</term>
<term>Adulte</term>
<term>Toxicité</term>
<term>Ergot dérivé</term>
<term>Fluctuation motrice</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In this 12-week, randomized, open-label, blinded-rater, parallel-group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.), with a possible increase to 200 mg t.i.d., or pergolide titrated to a maximum dose of 5 mg/day by week 9 (mean final dose 2.2 mg/day). The trial involved 203 patients. Efficacy variables that decreased from baseline to week 12 with tolcapone and pergolide included "off" time (reduced by 2-3 hours/day), daily levodopa intake, sickness impact profile scores, Parkinson's disease questionnaire (PDQ)-39 scores, and Unified Parkinson's Disease Rating Scale (UPDRS) scores. Improvements in efficacy variables were similar with tolcapone and pergolide, with the exception of improvements in quality of life, which were significantly greater with tolcapone; the relative changes in PDQ-39 score at week 12 were -8.7 and -14.2 (P < 0.05) with pergolide and tolcapone, respectively. Improvements in the investigator's global assessment (IGA) of overall efficacy were recorded in 86% of tolcapone-treated patients and in 78% of pergolide-treated patients. The proportion of patients who withdrew because of adverse events was higher in the pergolide group (15%) than in the tolcapone group (5%). Confusion, hypotension, nausea, constipation, abdominal pain, and dyspepsia occurred more frequently with pergolide, whereas diarrhea and urine discoloration occurred more frequently with tolcapone. Tolcapone was better tolerated than pergolide (P < 0.01) according to the IGA of overall tolerability. We conclude that, in this 3-month study, both tolcapone and pergolide provided improvements in motor fluctuations and allowed reductions in levodopa intake when added to levodopa therapy; intent to treat analysis and a less than maximal dose of pergolide may have biased the results in favor of tolcapone. Tolcapone provided greater improvements in quality of life, was better tolerated, and had a more favorable adverse-event profile than pergolide.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KOLLER (William)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LEES (Andrew)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DODER (Miroslava)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HELY (Mariese)</s1>
</fA11>
<fA14 i1="01"><s1>University of Miami</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Westmead Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>Tolcapone/Pergolide Study Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>858-866</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000099256460080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>27 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0049768</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In this 12-week, randomized, open-label, blinded-rater, parallel-group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.), with a possible increase to 200 mg t.i.d., or pergolide titrated to a maximum dose of 5 mg/day by week 9 (mean final dose 2.2 mg/day). The trial involved 203 patients. Efficacy variables that decreased from baseline to week 12 with tolcapone and pergolide included "off" time (reduced by 2-3 hours/day), daily levodopa intake, sickness impact profile scores, Parkinson's disease questionnaire (PDQ)-39 scores, and Unified Parkinson's Disease Rating Scale (UPDRS) scores. Improvements in efficacy variables were similar with tolcapone and pergolide, with the exception of improvements in quality of life, which were significantly greater with tolcapone; the relative changes in PDQ-39 score at week 12 were -8.7 and -14.2 (P < 0.05) with pergolide and tolcapone, respectively. Improvements in the investigator's global assessment (IGA) of overall efficacy were recorded in 86% of tolcapone-treated patients and in 78% of pergolide-treated patients. The proportion of patients who withdrew because of adverse events was higher in the pergolide group (15%) than in the tolcapone group (5%). Confusion, hypotension, nausea, constipation, abdominal pain, and dyspepsia occurred more frequently with pergolide, whereas diarrhea and urine discoloration occurred more frequently with tolcapone. Tolcapone was better tolerated than pergolide (P < 0.01) according to the IGA of overall tolerability. We conclude that, in this 3-month study, both tolcapone and pergolide provided improvements in motor fluctuations and allowed reductions in levodopa intake when added to levodopa therapy; intent to treat analysis and a less than maximal dose of pergolide may have biased the results in favor of tolcapone. Tolcapone provided greater improvements in quality of life, was better tolerated, and had a more favorable adverse-event profile than pergolide.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>235</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Tolcapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Tolcapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tolcapona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>09</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>09</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>09</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Pergolida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Agonist</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Agonista</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Randomization</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Treatment</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Drug combination</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>23</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>23</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Ergot dérivé</s0>
<s5>31</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Ergot derivatives</s0>
<s5>31</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Ergot derivado</s0>
<s5>31</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Fluctuation motrice</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>021</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000386 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000386 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:02-0049768
   |texte=   Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri